Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share.

The report summarises Orthocell’s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+.

The author noted:

“FY24 saw OCC’s Remplir and Striate products continue to gain traction after ~18 months on market. OCC is now focused on expanding the global footprint of both products. It is targeting 7 new markets, while continuing to execute on growing revenues from existing markets and progressing partnering process for Remplir and non-core tendon cell therapy (with the appointment of US advisors). A renewed Board and strong cash position are supporting this effort. We reiterate BUY, with our $1.28/sh TP offering >3x upside.”

Click here to read the report.

Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).

Read more

Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned for its medical device platform products.

Read more

Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+™, in the key market of Canada.

Read more

Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million – up 30.40% from the previous financial year, FY23.

Read more